Douglas Lane & Associates LLC Decreases Position in Kenvue Inc. (NYSE:KVUE)

Douglas Lane & Associates LLC decreased its position in Kenvue Inc. (NYSE:KVUE) by 59.8% during the 4th quarter, Holdings Channel.com reports. The firm owned 92,720 shares of the company’s stock after selling 137,882 shares during the period. Douglas Lane & Associates LLC’s holdings in Kenvue were worth $1,980,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also bought and sold shares of the company. Riverview Trust Co purchased a new position in shares of Kenvue in the third quarter worth about $30,000. Ashton Thomas Securities LLC bought a new stake in Kenvue during the 3rd quarter valued at $35,000. Versant Capital Management Inc lifted its position in shares of Kenvue by 300.8% during the fourth quarter. Versant Capital Management Inc now owns 1,920 shares of the company’s stock worth $41,000 after acquiring an additional 1,441 shares in the last quarter. Studio Investment Management LLC boosted its holdings in shares of Kenvue by 52.1% in the second quarter. Studio Investment Management LLC now owns 2,468 shares of the company’s stock worth $45,000 after acquiring an additional 845 shares during the period. Finally, Deseret Mutual Benefit Administrators grew its position in shares of Kenvue by 49.7% in the third quarter. Deseret Mutual Benefit Administrators now owns 1,960 shares of the company’s stock valued at $45,000 after purchasing an additional 651 shares in the last quarter. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on the company. Piper Sandler raised Kenvue from a “neutral” rating to an “overweight” rating and increased their price objective for the stock from $21.00 to $26.00 in a report on Monday. Deutsche Bank Aktiengesellschaft downgraded shares of Kenvue from a “buy” rating to a “hold” rating and lowered their price target for the stock from $25.00 to $24.00 in a report on Thursday, December 12th. Jefferies Financial Group initiated coverage on shares of Kenvue in a report on Tuesday, September 24th. They set a “buy” rating and a $27.00 target price on the stock. Bank of America raised their price target on shares of Kenvue from $24.00 to $27.00 and gave the company a “buy” rating in a report on Tuesday, October 22nd. Finally, Royal Bank of Canada raised shares of Kenvue from a “hold” rating to a “moderate buy” rating in a report on Monday, December 9th. One analyst has rated the stock with a sell rating, seven have issued a hold rating and four have assigned a buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $23.09.

Kenvue Stock Up 0.1 %

KVUE opened at $21.07 on Thursday. The business’s fifty day simple moving average is $22.73 and its 200 day simple moving average is $21.56. Kenvue Inc. has a 52 week low of $17.67 and a 52 week high of $24.46. The company has a quick ratio of 0.69, a current ratio of 1.00 and a debt-to-equity ratio of 0.66. The stock has a market cap of $40.40 billion, a PE ratio of 38.31, a P/E/G ratio of 2.02 and a beta of 1.46.

Kenvue (NYSE:KVUE) last announced its quarterly earnings data on Thursday, November 7th. The company reported $0.28 EPS for the quarter, beating the consensus estimate of $0.27 by $0.01. The firm had revenue of $3.90 billion for the quarter, compared to analyst estimates of $3.92 billion. Kenvue had a return on equity of 21.43% and a net margin of 6.88%. The company’s revenue was down .4% on a year-over-year basis. During the same period in the prior year, the company earned $0.31 EPS. As a group, research analysts expect that Kenvue Inc. will post 1.07 earnings per share for the current fiscal year.

Kenvue Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Wednesday, November 27th. Shareholders of record on Wednesday, November 13th were paid a $0.205 dividend. This represents a $0.82 annualized dividend and a yield of 3.89%. The ex-dividend date was Wednesday, November 13th. Kenvue’s dividend payout ratio is presently 149.09%.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.